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Background: Little is known about the effect of combination anti-
retroviral therapy (cART) on life expectancy in sub-Saharan Africa.
Objective: To estimate life expectancy of patients once they initiate
cART in Uganda.
Design: Prospective cohort study.
Setting: Public sector HIV and AIDS disease-management program
in Uganda.
Patients: 22 315 eligible patients initiated cART during the study
period, of whom 1943 were considered to have died.
Measurements: All-cause mortality rates were calculated and
abridged life tables were constructed and stratified by sex and
baseline CD4 cell count status to estimate life expectancies for
patients receiving cART. The average number of years remaining to
be lived by patients who received cART at varying age categories
was estimated.
Results: After adjustment for loss to follow-up, crude mortality
rates (deaths per 1000 person-years) ranged from 26.9 (95% CI,
25.4 to 28.5) in women to 43.9 (CI, 40.7 to 47.0) in men. For
patients with a baseline CD4 cell count less than 0.050  10
9
cells/L, the mortality rate was 67.3 (CI, 62.1 to 72.9) deaths per
1000 person-years, whereas among persons with a baseline CD4
cell count of 0.250  10
9 cells/L or more, the mortality rate was
19.1 (CI, 16.0 to 22.7) deaths per 1000 person-years. Life expec-
tancy at age 20 years for the overall cohort was 26.7 (CI, 25.0 to
28.4) additional years and at age 35 years was 27.9 (CI, 26.7 to
29.1) additional years. Life expectancy increased substantially with
increasing baseline CD4 cell count. Similar trends are observed for
older age groups.
Limitations: A small (6.4%) proportion of patients were lost to
follow-up, and it was imputed that 30% of these patients had died.
Few patients with a CD4 cell count greater than 0.250  10
9
cells/L initiated cART.
Conclusion: Ugandan patients receiving cART can expect an al-
most normal life expectancy, although there is considerable vari-
ability among subgroups of patients.
Primary Funding Source: Canadian Institutes of Health Research.
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I
ncreased access to combination antiretroviral therapy
(cART) has led to a substantial decrease in morbidity and
mortality among patients who are HIV positive in
resource-constrained settings (1, 2). The effect of increased
survival has allowed patients who are HIV positive and
receiving cART to contribute to their family and local
economies and social structure (3–5).
Life expectancy and mortality are important indicators
of population health. Studies have shown a negative rela-
tionship between HIV prevalence and life expectancy at a
population level (6). A recent collaborative cohort analysis
by the Antiretroviral Therapy (ART) Cohort Collaboration
demonstrated that patients in Europe and the United
States initiating cART at age 20 years could expect to live
an additional 49 years, with an overall increase of 81% in
life expectancy since 1996 (7). This group also showed that
men had lower life expectancy than women and that life
expectancy improved with increasing baseline CD4 cell
count status (7).
In contrast, the long-term life expectancy of pa-
tients receiving cART in resource-constrained settings is
unclear and remains speculative. Mortality estimates
vary, owing to small sample sizes, overrepresentation of
certain groups, high rates of loss to follow-up, and as-
sociated misclassiﬁcation of mortality (1, 8, 9). Sub-
optimal initial drug regimens and co-infection with
chronic untreated comorbid conditions, such as tuber-
culosis, hepatitis, and malnutrition, are also problematic
in resource-constrained settings and may affect life ex-
pectancy (10–12). Knowledge about life expectancy of
patients infected with HIV in resource-limited settings
is of critical importance at individual and population
levels as prognostic and effectiveness indicators and with
regard to investment in cART rollout programs.
In Uganda, life expectancy at birth is approximately
55 years and increases as persons survive key milestone ages
(13). By using data from a national cohort of patients with
HIV in Uganda, we estimated life expectancy among a
large, nationally representative cohort of persons receiving
free cART.
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Participants
Our study used data collected by The AIDS Support
Organization (TASO). This organization provides clinical
care, psychosocial support, and antiretroviral therapy to
persons with HIV at 11 major clinical sites and 35 smaller
clinics throughout Uganda, involving both urban and rural
populations. This organization began providing wide-
spread cART in 2004 with resource support from the U.S.
President’s Emergency Plan for AIDS Relief. More than
24 000 patients are currently receiving this treatment, and
more than 80 000 patients await cART initiation. Criteria
for starting antiretroviral therapy include having a World
Health Organization (WHO) stage 3 or 4 diagnosis or a
CD4 cell count status of less than 0.250  10
9 cells/L
(14). The Uganda Ministry of Health National Antiretro-
viral Treatment and Care Guidelines for Adults and Chil-
dren does not yet reﬂect the WHO’s newest recommenda-
tions for immunologic classiﬁcation and initiation of cART
(0.350  10
9 cells/L) (15). Patients initiating antiretro-
viral therapy typically receive a nonnucleoside reverse tran-
scriptase inhibitor with ﬁrst-line treatment with ﬁxed-dose
combinations comprising nevirapine or efavirenz plus
lamivudine and stavudine; second-line therapy consists of
boosted lopinavir, didanosine, and zidovudine (16, 17).
Data Collection
Detailed demographic information, clinical character-
istics, and treatment information were collected on stan-
dardized forms at each patient visit. These data are entered
into a centralized clinical database at TASO and are fre-
quently used for research purposes (18–23). When en-
rolled at TASO, each patient is provided with a unique,
coded identiﬁcation number. Adherence-monitoring teams
are used to undertake patient retention and follow-up; they
visit all patients who do not show up for any appointment
or who have requested home-based care. Mortality status is
actively pursued to determine vital statistics. The teams
consist of medical attendants capable of HIV testing, ad-
herence counseling, clinical observation, and providing an-
tiretroviral therapy.
For this study, we included all patients aged 14 years
or older who initiated antiretroviral therapy at TASO clin-
ics in Uganda from 1 January 2000 to 31 December 2009.
Age 14 years is when adolescents are classiﬁed as receiving
adult care. Patients were followed until either time of con-
ﬁrmed death or end of the study (1 January 2010). The
following patient information was recorded: age of the pa-
tient and year that antiretroviral therapy was started, sex of
the patient, baseline CD4 cell count status, and WHO
clinical disease stage. If the patient was lost to follow-up (a
3-month absence from a clinic), the date when he or she
was last seen and the date of death (if applicable) was
recorded.
The ethics review board at the headquarters of TASO
Uganda, Mbale Regional Referral Hospital (Mbale,
Uganda), and the research ethics boards of the University
of British Columbia and the University of Ottawa ap-
proved the conduct of this study.
Statistical Analysis
We assessed demographic information on patients be-
fore and after 2006, the year that the projects funded by
the U.S. President’s Emergency Plan for AIDS Relief ex-
panded most rapidly. We examined whether mortality dif-
fered before compared with after the expansion period.
We did a series of demographic and statistical anal-
yses. To correct for potential misclassiﬁcation of death
among persons recorded as lost to follow-up, we conser-
vatively estimated that 30% who were lost to follow-up
had died; this estimation is based on results of a de-
faulter tracing study done in semiurban Uganda (24,
25). Among persons lost to follow-up, patients were
weighted equally by age and CD4 cell count status, such
that higher weight would go to persons who were older
and had lower CD4 cell counts (18, 23). In doing so,
patients with a higher weight would be very likely to be
assigned as a death. Of this 30%, the date of last contact
remained as the censor date. We applied Markov chain
Monte Carlo methods of multiple imputation for miss-
ing CD4 cell count status and WHO stage information.
The variables used to impute the missing values in-
cluded age, follow-up time, and year of ﬁrst cART
through SAS PROC MI (SAS software, version 9.1, SAS
Institute, Cary, North Carolina).
Mortality rates were calculated by dividing the total
number of deaths by the total number of person-years of
follow-up. The mortality rates are expressed as deaths per
1000 person-years, stratiﬁed by sex (men or women) and
Context
Combination antiretroviral therapy has dramatically in-
creased life expectancy in persons with HIV infection in
the United States and northern Europe, but its effect in
resource-constrained countries is unknown.
Contribution
Treatment with combination regimens increased life ex-
pectancy to nearly normal levels in persons infected with
HIV in Uganda. Women derived greater benefit than men,
as did patients who began therapy at higher CD4 cell
counts.
Caution
Some data were missing. Regimens were older and more
toxic than those in use in developed countries.
Implication
Antiretroviral therapy for HIV infection can dramatically
increase life expectancy in Africa, where the burden of
disease is greatest.
—The Editors
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0.149, 0.150 to 0.249, and 0.250  10
9 cells/L).
Potential years of life lost (PYLL) up to the age of 55
years was used to examine the effect of HIV on premature
mortality. The PYLL estimates the average years a person
or group would have lived if they had not died prema-
turely. This number was calculated by taking the total
number of deaths in each 5-year age group and multiplying
the average number of years remaining in that age group
up to age 55 years—the approximate life expectancy at
birth in Uganda (13). The PYLL was expressed per 1000
person-years from age 14 to 54 years (26). Values were
stratiﬁed by sex and baseline CD4 cell count status.
Death during follow-up was analyzed by using Kaplan–
Meier methods and the Cox proportional hazards model.
Covariates of interest included age, sex, year of ﬁrst cART,
WHO stage, and CD4 cell count status (27). Hazard pro-
portionality was assessed by using analysis of scaled Schoen-
feld residuals.
Abridged life tables were constructed from age-speciﬁc
mortality rates by using methods established by Chiang
(28). Life expectancy estimated from this type of life table
is viewed as depicting the lifetime mortality experience of a
single cohort of persons who are subject to the mortality
schedules on which the table is constructed. Therefore, life
expectancy at an exact age is an indicator measuring the
average number of additional years that will be lived by a
person after that age, according to the age-speciﬁc mortal-
ity rates for all deaths during the study period. Because a
very large population and number of deaths are required to
overcome variations in mortality when constructing a com-
plete life table by single years, we used abridged life tables
by aggregated age groups, which describe the effect of mor-
tality on a sample of persons if they were subjected to the
mortality rates in the observed calendar periods (29, 30).
Life expectancy was reported from age 20 to 55 years in
5-year intervals with 95% CIs. Life expectancy values were
stratiﬁed by sex and baseline CD4 cell count status. De-
tailed methods on life expectancy approaches are widely
available (28, 29, 31). The Appendix Table (available at
www.annals.org) displays the life table approach, and the
Appendix (available at www.annals.org) provides a worked
example.
All signiﬁcance tests were 2-sided, and P values of less
than 0.05 were considered statistically signiﬁcant. All anal-
yses were done by using SAS software, version 9.1 (SAS
Institute); R software, version 2.7.1 (R Foundation for Sta-
tistical Computing, Vienna, Austria); and Microsoft Excel
2008 (Microsoft, Seattle, Washington).
Role of the Funding Source
The Canadian Institutes of Health Research sponsored
the study. The funding source had no role in the design,
conduct, or collection of data; in the analysis or interpre-
tation of the study; or in the decision to submit the man-
uscript for publication.
RESULTS
Our analyses were based on a cohort of 22 315 persons
aged 14 years or older who initiated cART at TASO clinics
in Uganda from 2000 to 2009, contributing a total of
59 436 person-years. A total of 9899 patients who initiated
cART from 2000 to 2006 were followed for median of 48
months (interquartile range [IQR], 38 to 55 months) and
12 416 patients who initiated cART from 2007 to 2009
were followed for a median of 24 months (IQR, 17 to 31
months). Table 1 shows baseline characteristics of patients.
The median age was similar in both periods of therapy
initiation: 37 years (IQR, 32 to 44 years) for 2000 to 2006
and 37 years (IQR, 31 to 43 years) for 2007 to 2009.
Larger proportions of women initiated therapy in the ear-
lier period (71.8% for 2000 to 2006 vs. 67.5% for 2007 to
2009; P  0.001). The median CD4 cell count increased
slightly over time: 0.126  10
9 cells/L (IQR, 0.060 to
Table 1. Baseline Characteristics of Patients
Characteristic Overall
Patients, n
Patients, n (%)
2000–2006 2007–2009
Age
14–19 y 333 121 (1.2) 212 (1.7)
20–24 y 866y 270 (2.7) 596 (4.8)
25–29 y 2620 1017 (10.3) 1603 (12.9)
30–34 y 4801 2146 (21.7) 2655 (21.4)
35–39 y 4973 2286 (23.1) 2687 (21.6)
40–44 y 3944 1871 (18.9) 2073 (16.7)
45–49 y 2348 1084 (11.0) 1264 (10.2)
50–54 y 1271 589 (6.0) 682 (5.5)
55 y 1159 515 (5.2) 644 (5.2)
Sex
Men 6823 2787 (28.2) 4036 (32.5)
Women 15 492 7112 (71.8) 8380 (67.5)
CD4 count
0.050  10
9 cells/L 3452 1698 (21.1) 1754 (16.8)
0.050–0.099  10
9
cells/L
2942 1458 (18.1) 1484 (14.2)
0.100–0.149  10
9
cells/L
3410 1662 (20.7) 1748 (16.7)
0.150–0.249  10
9
cells/L
5740 2506 (31.2) 3234 (30.9)
0.250  10
9 cells/L 2954 720 (9.0) 2234 (21.4)
Missing 3817
WHO stage
1 465 227 (4.2) 238 (2.6)
2 7985 2511 (47.0) 5474 (58.8)
3 4982 2232 (41.8) 2750 (29.6)
4 1220 376 (7.0) 844 (9.1)
Missing 7663
Death
No 20 817 8916 (90.1) 11 901 (95.9)
Yes 1498 983 (9.9) 515 (4.1)
Lost to follow-up
No 20 882 9160 (92.5) 11 722 (94.4)
Yes 1433 739 (7.5) 694 (5.6)
WHO  World Health Organization.
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9 cells/L) for 2000 to 2006 versus 0.156  10
9
cells/L (IQR, 0.080 to 0.230  10
9 cells/L) for 2007 to
2009. Most patients initiated therapy at WHO stage 2 or 3
in both periods (88.8% for 2000 to 2006 and 88.4% for
2007 to 2009). A total of 1498 (6.7%) deaths were re-
corded in the cohort from 2000 to 2009. An additional
1433 (6.4%) were reported as lost to follow-up. A total of
30% of persons who were lost to follow-up were assumed
to have died, making the total number of estimated deaths
in the cohort to be 1943. This value was used for all sub-
sequent analyses.
The crude mortality rate was 31.8 (95% CI, 30.3 to
33.2) deaths per 1000 person-years for the overall cohort.
The PYLL was 795.0 years per 1000 person-years for the
overall cohort. Women had a lower mortality rate than
men: 26.9 (CI, 25.4 to 28.5) versus 43.9 (CI, 40.7 to 47.0)
deaths per 1000 person-years, respectively. Similarly, PYLL
was less for women than men (689.7 vs. 995.9 years per
1000 person-years). The mortality rate and PYLL de-
creased substantially with increasing baseline CD4 cell
count status. For patients with a baseline CD4 cell count
less than 0.050  10
9 cells/L, the mortality rate was 67.3
(CI, 62.1 to 72.9) deaths per 1000 person-years. For pa-
tients with CD4 cell counts of 0.050 to 0.099  10
9
cells/L, it was 36.8 (32.9 to 41.2). For patients with CD4
cell counts of 0.100 to 0.149  10
9 cells/L, it was 27.5
(24.4 to 31.0). For patients with CD4 cell counts of 0.150
to 0.249  10
9 cells/L, it was 20.2 (18.1 to 22.6). Among
patients with baseline CD4 cell counts of 0.250  10
9
cells/L or more, the mortality rate was 19.1 (CI, 16.0 to
22.7) deaths per 1000 person-years. Similarly, the PYLL
among patients with a baseline CD4 cell count status less
than 0.050  10
9 cells/L was much higher (1813.3 per
1000 person-years) than in those with a baseline CD4 cell
count of 0.250  10
9 cells/L or more (435.5 per 1000
Figure. Kaplan–Meier product limit estimates for probability
of survival, by age group.
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cART  combination antiretroviral therapy.
Table 2. Cox Proportional Hazards of Time to Death Among Persons Receiving Combination Antiretrovival Therapy in Uganda*
Variable Unadjusted HR (95% CI) P Value Adjusted HR (95% CI) P Value
Age
14–19 y 0.83 (0.57–1.21) 0.33 0.81 (0.55–1.18) 0.263
20–29 y 0.81 (0.69–0.95) 0.012 0.83 (0.70–0.98) 0.026
30–39 y 0.75 (0.65–0.86) 0.001 0.73 (0.63–0.84) 0.001
40–49 y 0.72 (0.62–0.84) 0.001 0.70 (0.60–0.81) 0.001
50 y 1.00 (NA) NA 1.00 (NA) NA
Sex
Men vs. women 1.53 (1.40–1.68) 0.001 1.47 (1.34–1.62) 0.001
WHO stage at baseline
1 1.00 (NA) NA 1.00 (NA) NA
2 1.21 (0.77–1.91) 0.38 1.31 (0.87–1.98) 0.180
3 2.30 (1.43–3.70) 0.002 2.18 (1.43–3.32) 0.001
4 4.14 (2.72–6.31) 0.001 4.00 (2.75–5.82) 0.001
CD4 count at baseline†
0.050  10
9 cells/L 1.00 (NA) NA 1.00 (NA) NA
0.050–0.099  10
9 cells/L 0.61 (0.53–0.70) 0.001 0.65 (0.56–0.75) 0.001
0.100–0.149  10
9 cells/L 0.48 (0.41–0.55) 0.001 0.53 (0.45–0.63) 0.001
0.150–0.249  10
9 cells/L 0.35 (0.31–0.40) 0.001 0.42 (0.37–0.47) 0.001
0.250  10
9 cells/L 0.32 (0.27–0.37) 0.001 0.39 (0.34–0.46) 0.001
Year of first cART 0.74 (0.72–0.77) 0.001 0.75 (0.72–0.78) 0.001
cART  combination antiretroviral therapy; HR  hazard ratio; NA  not applicable; WHO  World Health Organization.
* Results from multiple-imputation method.
† Categorical.
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tality by sex (odds ratio, 0.95 [CI, 0.59 to 1.54]; P 
0.86).
The Figure shows the Kaplan–Meier product limit es-
timates of survival by age. The estimated probability of
survival after 36 months of follow-up was 90.7% (CI,
87.0% to 94.4%); 93.4% (CI, 91.3% to 95.4%); 93.0%
(CI, 91.1% to 95.0%); 93.2% (CI, 91.3% to 95.3%), and
90.9% (CI, 89.03% to 92.9%) for age groups 14 to 19
years, 20 to 29 years, 30 to 39 years, 40 to 49 years, and
older than 50 years, respectively.
Table 2 summarizes the unadjusted and adjusted Cox
regression of factors associated with survival time based on
multiple-imputation results. The adjusted model indicates
a strong association between baseline CD4 cell count status
and mortality when age, WHO stage, year of ﬁrst cART,
and sex are controlled for. Relative to a baseline CD4 cell
status of less than 0.050  10
9 cells/L, the adjusted hazard
ratio associated with mortality decreased to 0.65 (CI, 0.56
to 0.75), 0.53 (CI, 0.45 to 0.63), 0.42 (CI, 0.37 to 0.46),
and 0.39 (CI, 0.34 to0.46) for baseline CD4 cell count of
0.050 to 0.099, 0.100 to 0.149, 0.150 to 0.249, and
0.250  10
9 cells/L or more, respectively. Mortality was
signiﬁcantly increased according to the year of cART ini-
tiation, with patients starting therapy earlier having worse
outcomes (P  0.001).
Life expectancy for the overall cohort was 26.7 years
(CI, 25.0 to 28.4 years) at age 20 years and 27.9 years (CI,
26.7 to 29.1 years) at age 35 years (Table 3) of additional
life. Men had consistently shorter life expectancy than
women. Life expectancy at age 20 years was 19.1 years (CI,
16.6 to 21.6 years) for men and 30.6 years (CI, 28.7 to
32.5 years) for women; at age 35 years, life expectancy was
22.0 years (CI, 20.6 to 23.4 years) for men and 32.5 years
(CI, 31.1 to 33.9 years) for women. Life expectancy in-
creased substantially with increasing baseline CD4 cell
count status; for patients with a baseline CD4 cell count
status of less than 0.050  10
9 cells/L had a life expectancy
of 13.5 years (CI, 11.6 to 15.4 years) and 14.2 years (CI,
12.8 to 15.6 years) at exact age 20 and 35 years, respec-
tively, and patients with a CD4 cell count status of
0.250  10
9 cells/L or more had a life expectancy of 37.4
years (CI, 34.2 to 40.6 years) and 35.1 years (CI, 33.0 to
37.2 years) at exact age 20 and 35 years, respectively.
DISCUSSION
To our knowledge, this study is the ﬁrst formal eval-
uation of life expectancy of patients with HIV in an Afri-
can setting. We found that antiretroviral therapy in
Uganda offers favorable life expectancy compared with the
national average. We found that life expectancies varied
considerably according to sex, with women having a
greater life expectancy than men, and that higher baseline
CD4 cell count status at treatment initiation strongly in-
dicates potential life expectancy.
Table 3. Life Expectancy Overall and by Sex Among Persons Receiving Combination Antiretroviral Therapy in Uganda
Age General Ugandan Life Expectancy
(WHO), y
Life Expectancy (95% CI), y
Overall Men Women
14–19 y 45.9* 26.2 (23.7–28.7) 22.2 (18.5–25.8) 27.9 (24.5–31.4)
20–24 y 41.6 26.7 (25.0–28.4) 19.1 (16.6–21.6) 30.6 (28.7–32.5)
25–29 y 37.4 28.1 (26.8–29.4) 21.3 (19.5–23.1) 32.3 (30.8–33.8)
30–34 y 33.5 28.2 (27.0–29.4) 21.8 (20.3–23.3) 32.8 (31.4–34.2)
35–39 y 30.1 27.9 (26.7–29.1) 22.0 (20.6–23.4) 32.5 (31.1–33.9)
40–44 y 27.1 26.9 (25.7–28.1) 21.9 (20.5–23.3) 31.3 (30.0–32.6)
45–49 y 24.3 25.4 (24.3–26.5) 20.9 (19.5–22.3) 29.6 (28.3–30.9)
50–54 y 21.3 24.0 (22.9–25.1) 20.2 (18.9–21.5) 27.8 (26.6–29.0)
55 y NA 22.6 (NA) 19.2 (NA) 26.2 (NA)
Age Life Expectancy by CD4 Count (95% CI), y
<0.050
 10
9 cells/L
0.050–0.099
 10
9 cells/L
0.100–0.149
 10
9 cells/L
0.150–0.249
 10
9 cells/L
>0.250
 10
9 cells/L
14–19 y 11.8 (8.8–14.7) 21.0 (14.6–27.4) 38.1 (NA) 40.2 (32.7–47.6) 43.4 (NA)
20–24 y 13.5 (11.6–15.4) 23.1 (20.4–25.8) 32.1 (28.9–35.3) 40.5 (37.7–43.3) 37.4 (34.2–40.6)
25–29 y 14.6 (13.1–16.1) 24.1 (22.1–26.1) 35.4 (33.0–37.8) 41.0 (38.9–43.1) 38.2 (35.8–40.6)
30–34 y 14.2 (12.8–15.6) 24.7 (22.9–26.5) 36.0 (33.8–38.2) 40.3 (38.4–42.2) 37.2 (35.1–39.3)
35–39 y 14.2 (12.8–15.6) 24.0 (22.2–25.8) 36.9 (34.8–39.0) 39.0 (37.2–40.8) 35.1 (33.0–37.2)
40–44 y 13.7 (12.2–15.2) 22.8 (21.0–24.6) 36.5 (34.4–38.6) 38.0 (36.2–39.8) 33.7 (31.7–35.7)
45–49 y 12.3 (10.8–13.8) 21.5 (19.8–23.2) 36.2 (34.1–38.3) 35.8 (34.0–37.6) 31.0 (29.1–32.9)
50–54 y 10.8 (9.3–12.3) 20.3 (18.8–21.8) 35.6 (33.6–37.6) 34.3 (32.7–35.9) 28.2 (26.4–30.0)
55 y 9.9 (NA) 18.1 (NA) 35.1 (NA) 33.2 (NA) 25.9 (NA)
NA  not available; WHO  World Health Organization.
* National estimate provided for persons aged 15 to 19 y. General life expectancy of each group in column 2 is obtained from the WHO Global Health Observatory
Database (13). No CIs are provided for the oldest age category because the upper interval of age was open.
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decreases in mortality and increases in life expectancy with
access to cART (7, 32, 33). The ART Cohort Collabora-
tion evaluation of 18 587 patients from 14 high-income
cohorts initiating cART from 1996 to 1999, when poorer
drug formulations were available, demonstrated that a pa-
tient aged 20 years could expect to survive an additional
36.1 years (7). By 2003 to 2005, when drug formulations
and understanding of treatments had increased, additional
life-years at age 20 years had increased to 49.4 years. These
studies have been conducted in Europe and in the United
States, where life expectancy at birth is substantially higher
than in African settings and where better access to health
services, particularly secondary and tertiary care for severely
ill patients, and lower rates of comorbid conditions have
probably contributed to more favorable outcomes. The
WHO Global Health Observatory estimates life expec-
tancy in Uganda at age 20 years as an additional 41 years
(13). Thus, despite poor baseline health and health care
facilities, the additional life years come close to what would
be expected in the general Uganda population, consistent
with higher income settings (7). As health care in Uganda
continues to improve, life expectancy will likely also im-
prove. Similarly, as patients have access to improved cART
drug regimens and routinely access care at higher CD4
T-cell counts, we expect life expectancy to improve.
Consistent with previous studies from Europe and the
United States, we found that life expectancy varied accord-
ing to sex and baseline CD4 cell count. This ﬁnding builds
on an emerging body of literature displaying consistent
shortcomings in treatment programs involving men (8, 34,
35). Men typically access care at a later stage with more
advanced disease and have higher rates of mortality and
loss to follow-up than women (8, 18). We also found that
low CD4 cell count status at baseline was strongly predic-
tive of lower life expectancy, a ﬁnding supportive of the
latest WHO recommendation to start treatment at higher
CD4 cell counts (15). Unfortunately, accessing and treat-
ing patients at early stages can be a challenge for both
health infrastructure and identifying patients. In Uganda,
the ministry of health guidelines do not yet recommend
treatment of patients with cART until CD4 cell count
status is less than 0.250  10
9 cells/L, and the median
CD4 cell count of patients initiating treatment in our co-
hort was far less, at 0.156  10
9 cells/L. Patients with
higher CD4 cell count status (0.250  10
9 cells/L) will
typically have been allowed to begin therapy because of
active tuberculosis, WHO stage 3 or 4 disease, or preg-
nancy, in keeping with national guidelines (14). This ex-
plains why life expectancy in patients with the highest clas-
siﬁcation of CD4 cell count (0.250  10
9 cells/L) was
slightly less than that of patients with a CD4 cell count
status in the more moderate classiﬁcation (0.150 to 0.249
CD4  10
9 cells/L).
In our analysis, adolescents (14 to 19 years) had worse
life expectancy than older patients (20 to 49 years). This is
because mortality among adolescents is usually higher than
in older age groups (36, 37). Adolescent patients are typi-
cally long-term survivors, infected at birth, who have sur-
vived to adolescence with only recently access to therapy.
In addition, adolescents may have important challenges in
adherence, response to therapy, and long-term suppression
(36). Efforts to expand HIV testing and improve pathways
to cART may help identify patients earlier, and efforts to
make treatment more accessible for patients may help ini-
tiate treatment earlier and, therefore, improve the effective-
ness of resources dedicated to cART.
One strength of our analysis is our nationally repre-
sentative sample, which includes a diverse population of
patients who would likely be found in other parts of Africa
(20, 38). Another strength is that our loss to follow-up is
low compared with most AIDS service organizations in
Africa, in which loss to follow-up can exceed 50% (9, 39),
because of our use of default tracers. However, we recog-
nize that there will be misclassiﬁcation of deaths among
patients lost to follow-up and attempted to correct for this
bias by applying an assumption that 30% of these patients
were dead (24). The fact that our analysis includes a rela-
tively small number of patients initiating therapy at high
CD4 cell count (0.250  10
9 cells/L) will probably have
reduced our estimate of life expectancy at the very highest
CD4 baseline status. Also, most patients began initiating
therapy after 2004, and thus, the number of years receiving
cART is variable. This possibly affects the stability of our
projections, although our overall number of life-years is
large (30).
A total of 3817 patients did not have baseline CD4
cell count evaluations, so we imputed them. Missing initial
CD4 cell count is common in programs across Africa, ow-
ing to clinical circumstances or poor laboratory infrastruc-
ture. We explored the effect of these patients on our overall
analysis and did not ﬁnd a different effect (data not
shown). TASO does not conduct routine viral-load assess-
ments, and therefore, we cannot make inferences about
risks for treatment failure on life expectancy, although
other studies have shown that clinically driven care out-
comes are similar to laboratory-informed care in the short
term (40). Finally, as with any observational study, our
mortality rate may be subject to residual confounding be-
yond those confounders adjusted for in multivariate
analysis.
The substantial life expectancy afforded by widespread
access to cART underscores the fact that HIV diagnosis in
resource-limited settings is no longer a death sentence.
Viewing HIV and AIDS as a chronic disease implies that
models of care need to be developed to ensure that fragile
health systems do not become overwhelmed with a grow-
ing caseload of asymptomatic persons; such models of
home-based cART are already being tested in Uganda,
with demonstrated efﬁcacy (41). In our analysis, older pa-
tients (55 years or older) had the highest mortality rates.
Important future challenges include development of
Original Research Life Expectancy of Persons Receiving Antiretroviral Therapy in Uganda
214 16 August 2011 Annals of Internal Medicine Volume 155 • Number 4 www.annals.orgchronic disease management among patients—particularly
elderly persons—because most resource-limited settings
are unable to provide care for comorbid conditions, such as
cardiovascular and neurologic disease (23).
We believe that our study is generalizable to Uganda
and to many other settings in Africa in which patients
access simpliﬁed HIV/AIDS care in rural, semirural, and
urban settings. The TASO clinics serve all major regions of
Uganda and cover broad populations involving children;
men and women; and vulnerable populations, including
adolescents, internally displaced persons, and persons expe-
riencing economic and food insecurity (20, 38). The orga-
nization provides care in both clinic-based services as well
as decentralized care to serve persons who are geographi-
cally distant from clinics. This approach has been shown to
result in outcomes similar to those of clinic-based care
(41).
In summary, our study adds to the growing body of
evidence that the beneﬁts of cART are many and extend
well beyond reduced early mortality. Widespread access to
cART includes a reduction in the incidence of tuberculosis
(42), reduced transmission of HIV (43), and increased pro-
ductivity and economic beneﬁts (44). These beneﬁts will
only be realized if there is continued support for antiretro-
viral scale-up by the international donor community and
national governments (45).
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APPENDIX
Mortality and PYLL
By using methods that we previously reported (7), we calcu-
lated mortality rates by age categories from the number of deaths
(Dx) in a given calendar year between exact age x and x  n and the
persons at risk who lived in that age interval and time period (Px).
Rates were expressed as deaths per 1000 person-years.
PYLL before age 55 years was used to examine the effect of
HIV on premature mortality. PYLL represents of the sum of
years that patients lost because of premature mortality. PYLL is a
convenient summary measure that accounts for not only the
number of deaths but also the ages at which death occurs. To
obtain PYLL, the total number of deaths for a particular cause in
each 5-year age group is multiplied by the average number of
years remaining in that age group to age 55 years, as follows:
PYLL di55  Yi
where Yi is the age at the midpoint of age group i.
Life Tables
The abridged life tables were constructed by using techniques
described by Chiang (28). Life-expectancy values were reported from
age 14 years to older than 55 years. The rows in the life tables refer
to exact age groups. The columns in the life tables include the fol-
lowing functions (note that the sufﬁx x refers to an exact age and the
preﬁx n refers to the length of an age group):
x, n: The period of life between 2 exact ages (x and x 
n)—e.g., when x  20 and n  5, this means the 5-year interval
between the 20th and 25th birthdays.
nmx: The death rate in the population between exact age x
and exact age x  n.
nqx: The proportion of people in the population who reach
exact age x who are not still living at exact age x  n.
lx: The number of survivors from a hypothetical cohort at
exact age x.
ndx: The number of members of a hypothetical cohort who
die between exact age x and exact age x  n.
nLx: The number of person-years lived by members of a
hypothetical cohort between exact ages x and x  n.
Tx: The number of person-years lived by a hypothetical co-
hort above exact age x;
e
0
x: The expected number of years that a person in this
hypothetical cohort who reaches exact age x will live.
SEi: The SE of e
0
x.
The ﬁrst column in an abridged life table, nqx, is calculated
from crude age-speciﬁc population and death data. The nqx for-
mula in the construction of the abridged table is as follows:
qx 
nimx
1  1  ainimx
The age-speciﬁc death rate is expressed as mx, which is the quo-
tient of the number of deaths (Dx) in a given interval between
exact age x and x  n and the total number of person-years
at-risk in that age interval and period (Px).
mx 
Dx
Px
The trend in mortality does not vary much from one population
to another; therefore, ai can be regarded as a constant at most
ages. In these analyses, ai was assumed to be 0.5, as we presume
that deaths are evenly distributed. Finally, ni refers to the number
of years in each interval, which in this case would be 5. In the
open interval, qx is assumed to be 1.
The function lx refers to the survivors of a cohort of living
children to the exact age x. The initial value of this column, l0,i s
known as the radix, which was taken as 1000.
lxn  lx  dx
The function dx refers to the deaths experienced by the life table
cohort within the interval x to x  n. It can be obtained as follows:
dx  lxqx or dx  lx  lxn
The function Lx is the number of person-years lived by the co-
hort during the interval between x and x  n years. It can be
obtained as follows:
Lx  nilx  dx  ainidx
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summation of the Lx column, as follows:
Tx  Lx  Txn
The ﬁnal age interval in a life table is a half-open interval, which
is referred to as w. The following equations are used to estimate
Lw and Tw:
Lw 
lw
mw
Tw  Lw
The function e
0
x is the expectation of life remaining at exact age
x. The function is derived from the lx and Tx columns, as follows:
e0
x 
Tx
lx
The ﬁnal column refers to the standard error around the function
of e
0
x.
The following is an example using age category 14 to 19
years from the table below.
Proportion of people in the population who are not still
living:
qx 
nimx
1  1  ainimx

6  0.1020
1  1  0.5  6  0.1020
 0.4685
Death rate in the population:
mx 
Dx
Px

16
156.90
 0.1020
Survivors from a hypothetical cohort:
lxn  lx  dx
 1000  469
 531
Deaths from a hypothetical cohort:
dx  lx  lxn
 1000  531
 469
Number of person-years lived from a hypothetical cohort:
Lx  nilx  dx  ainidx
 6  1000  469  6  0.5  469
 4594
The number of person-years lived in a hypothetical cohort of
persons older than 20 to 24 years:
Tx  Lx  Txn
 4594  7164
 11758
The expected number of life-years remaining:
e0
x 
Tx
lx

11758
1000
 11.8
Appendix Table. Example of Life-Expectancy Analysis by Using Data From the TASO Data of Patients, at a CD4 Cell Count of 0 to
0.049  10
9 cells/L
Age (x) Number of
Years in
Category
(n)
Population-Years
at Risk (Px)
Number of
Deaths (Dx)
Mortality
Rate (mx)
Proportion
Surviving
Period (qx)
Alive at Start
of Interval (lx)
Probable
Deaths in
Hypothetical
Cohort (dx)
Person-Years
Lived in
Hypothetical
Cohort (Lx)
Person-Years
Lived Beyond
Start of
Interval (Tx)
Observed
Expectation
of Life (e0
x)
SE of e0
x
(SEi)
14–19 y 6 157 16 0.1020 0.4685 1000 469 4594 11758 11.8 1.50
20–24 y 5 365 32 0.0876 0.3594 531 191 2180 7164 13.5 0.96
25–29 y 5 1004 64 0.0638 0.2750 340 94 1468 4984 14.6 0.62
30–34 y 5 1794 125 0.0697 0.2967 247 73 1051 3516 14.2 0.53
35–39 y 5 1941 126 0.0649 0.2792 174 48 747 2464 14.2 0.53
40–44 y 5 1585 86 0.0543 0.2389 125 30 551 1718 13.7 0.56
45–49 y 5 873 54 0.0618 0.2677 95 25 412 1167 12.3 0.60
50–54 y 5 416 33 0.0794 0.3313 70 23 291 754 10.8 0.59
55 y  338 34 0.1006 1.0000 47 47 463 463 9.9 NA
NA  not applicable; TASO  The AIDS Support Organization.
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